Dr. Reddy's Laboratories Q1 FY26 Earnings Call Transcript

SEC Filing 6-K (0001575872-25-000510)

Dr. Reddy's Laboratories Limited reported its financial results for the first quarter of fiscal year 2026. The company achieved a double-digit revenue growth, with consolidated revenues standing at ₹8,545 crores ($997 million), an 11% year-on-year increase. The EBITDA margin was 26.7%, slightly above the company's target of 25%. The earnings call highlighted the company's strategic focus on complex generics, biosimilars, and consumer healthcare. Key developments included the progress of the biosimilar abatacept, which is expected to launch in early 2027, and the preparation for the launch of semaglutide in Canada and other markets. The company also discussed its cost optimization strategies and plans for future growth through strategic partnerships and acquisitions.